Keywords: Seattle Genetics, Adcetris, T-cell lymphoma, USA, FDA, Orphan designation, Takeda

FDA grants Seattle Genetics' Adcetris orphan rating in MF

Article | 27 November 2012

Print This

US biotech firm Seattle Genetics (Nasdaq: SGEN) says its Adcetris (brentuximab vedotin) has been granted orphan drug designation by the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in